AWA
HZNP

Arkadios Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Arkadios Wealth Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-62
Closed -$4K – 1797
2020
Q4 		$4K Sell
62
-6
-9% -$446 ﹤0.01% 1181
2020
Q3 		$5.41K Sell
68
-42
-38% -$2.89K ﹤0.01% 837
2020
Q2 		$6.18K Buy
+110
New +$4.71K ﹤0.01% 748

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Arkadios Wealth Advisors's HZNP Position: Q1 2021 in Review

Arkadios Wealth Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021, closing a stake of 62 shares — an estimated $4K sold.

Arkadios Wealth Advisors first reported a position in HZNP in Q2 2020 and held it in 3 quarters. The position peaked at $6.18K in Q2 2020. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

  • Arkadios Wealth Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2021 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 62 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $4K.
  • Arkadios Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 3 quarters.
  • Arkadios Wealth Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.18K in Q2 2020.
  • 516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2021, filed 26 Apr 2021.